Key Highlights:
- Gland Pharma’s Board has approved the acquisition of 100% of Gland Pharma USA Inc., currently a wholly owned step-down subsidiary, from Gland Pharma International Pte. Ltd. The move will make Gland US a direct wholly owned subsidiary.
- The USD 501,208 cash transaction is a related-party transaction being conducted at arm’s length based on an independent valuation. Gland Pharma expects to complete the acquisition by October 31, 2026.
- Gland US, incorporated in 2022, is engaged in the marketing and distribution of pharmaceutical products in the U.S. The restructuring is intended to remove corporate layers and streamline Gland Pharma’s structure, with no material impact expected on its business or operations.
Implications:
Gland Pharma’s move to acquire Gland Pharma USA Inc. directly from its Singapore intermediate holding company is a purely internal restructuring that removes one corporate layer between the Indian parent and its US marketing and distribution arm. The transaction, valued at about USD 0.5 million on an arm’s‑length basis, is not expected to change Gland’s business or operations; instead, it is aimed at simplifying the group structure, improving oversight of US activities, and making reporting and governance around the US subsidiary more straightforward.
Source: NSE
